Enjoy complimentary customisation on priority with our Enterprise License!
The global mono vaccine market size is estimated to grow by USD 2.8 billion between 2021 to 2026 accelerating at a CAGR of 5.16%.
This mono vaccine market report extensively covers market segmentation by Type (meningococcal vaccine, japanese encephalitis vaccine, hepatitis vaccine, yellow fever vaccine, and others) and Geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges.
Factors such as the increase in pediatric populations, initiatives taken by government agencies, recent drug development, and innovations in the market are propelling the growth of the market.
View the Bestselling Market Research Sample
The COVID-19 pandemic severely affected North American countries in 2020, disrupting the supply chain and manufacturing units of mono vaccines due to lockdowns. Pharmaceutical companies focused on developing COVID-19 vaccines and OTC drugs, reducing the production volume of mono vaccines. This had a negative impact on the market in 2020. However, the region's large-scale vaccination drive and investment in the pharmaceutical sector resumed operations in 2021, leading to expected growth in the regional mono vaccine market during the forecast period.
Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The rise in the number of newborn infants has led to a higher demand for combination vaccines for immunization, especially in developed countries with an increasing population of children due to immigration. However, developing regions such as India and China have a rapidly growing population due to low income, limited awareness of birth control, and improper implementation of birth control programs. The administration of human combination vaccines is recommended by the national health regulatory authority of each country to provide immunity against fatal diseases for infants and children. The prevalence of viral infections is high in developing nations, leading to an increased demand for human combination vaccines, driving the growth of the market during the forecast period.
The mono vaccine market is experiencing more mergers and acquisitions between companies to develop and sell drugs for infectious disease treatment. Market players are targeting fast-growing markets like India, Brazil, China, and South Africa, and to stay ahead, they are implementing M&A strategies to expand their product range and enhance their market position. Some recent examples of M and A are mentioned below:
Therefore, the rise in merger and acquisition activities across the globe is expected to boost market growth during the forecast period.
Developing vaccines is challenging due to sophisticated pathogen invasion mechanisms and limited understanding of specific immune responses, which can hinder the development process. Rapid pathogen phenotypic changes pose a major challenge, and lengthy clinical trials increase vaccine costs. Vaccines require proper storage conditions and a temperature-controlled supply chain to maintain efficacy. However, human error and equipment malfunctions can cause vaccine deterioration, particularly in resource-limited countries where storage guidelines are not followed. This hinders the growth of the market in focus during the forecast period.
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
En.biokangtai- The company, Shenzhen Kangtai Biological Products Co. Ltd. offers a mono vaccine, namely the SARS-COV 2 Vaccine.
The report also includes detailed analyses of the competitive landscape of the market and information about prominent and key market vendors, including:
Technavio’s report consists of a holistic analysis of the key development Analysis, development stage, key market players, their marketing strategies, and powerful innovations to help any client gain a competitive edge.
The mono vaccine market share growth in the Meningococcal Vaccine segment will be significant during the forecast period. Meningococcal meningitis is a type of meningitis caused by the Neisseria meningitidis bacteria, which can be transmitted from an infected person through direct contact with droplets from the throat or respiratory secretions. Asymptomatic carriers are also capable of transmitting the infection. Such prevalence of the meningococcal disease across the globe is expected to fuel the growth of the global mono vaccine market during the forecast period.
To gain further insights on the market contribution of various segments View Sample PDF
For more insights on the market share of various regions View PDF Sample now!
36% of the market’s growth will originate from North America during the forecast period. US, Germany, UK, France, and China are the key markets for mono vaccine market in North America. Market growth in this region will be slower than the growth in regions.
The increase in the pediatric population will facilitate the mono vaccine market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
Mono Vaccine Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.16% |
Market growth 2022-2026 |
USD 2.8 billion |
Market structure |
Concentrated |
YoY growth (%) |
4.2 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 36% |
Key consumer countries |
US, Germany, UK, France, and China |
Competitive landscape |
Leading companies, Competitive Strategies, Consumer engagement scope |
Key companies profiled |
AstraZeneca Plc, Aurobindo Pharma Ltd., Bavarian Nordic AS, China National Pharmaceutical Group Corp., Dynavax Technologies Corp., GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Moderna Inc., Pfizer Inc., Sanofi SA, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd., Valneva SE, and VBI Vaccines Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Type
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.